Cargando…

Study on the method to avoid infusion-site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells

The combination of intravenous Proemend(®) containing fosaprepitant meglumine, a prodrug for fosaprepitant (FAP), and Tween 80 and chemotherapy with anthracyclines, such as epirubicin (EPI), can cause infusion-site adverse events in clinical practice. In immortalized human umbilical vein endothelial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamasaki, Miho, Oda, Keisuke, Ichinose, Takashi, Mizuguchi, Marie, Tominaga, Shoko, Omoda, Kei, Mori, Nobuhiro, Maeda, Yorinobu, Nishida, Toshihiro, Murakami, Teruo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494625/ https://www.ncbi.nlm.nih.gov/pubmed/36238357 http://dx.doi.org/10.3892/ol.2022.13506

Ejemplares similares

Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant
por: Yamasaki, Miho, et al.
Publicado: (2019)

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant
por: Olver, Ian N
Publicado: (2008)

Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis
por: Burns, Derek, et al.
Publicado: (2020)

Interactions of Some Chemotherapeutic Agents as Epirubicin, Gemcitabine and Paclitaxel in Multicomponent Systems Based on Orange Essential Oil
por: Samide, Adriana, et al.
Publicado: (2021)

Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma.
por: Cho, Eun Kyung, et al.
Publicado: (2002)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
por: Langford, Patrick, et al.
Publicado: (2010)

Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives
por: Candelario, Nellowe, et al.
Publicado: (2016)

Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity
por: Yang, Fang, et al.
Publicado: (2017)

Reduction in the rate of postoperative delirium by switching from famotidine to omeprazole in Japanese hepatectomized recipients
por: Yamasaki, Miho, et al.
Publicado: (2019)

Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
por: Melcher, A. A., et al.
Publicado: (1996)

Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review
por: Eitsuka, Takahiro, et al.
Publicado: (2016)

Diagnosis by Microbial Culture, Breath Tests and Urinary Excretion Tests, and Treatments of Small Intestinal Bacterial Overgrowth
por: Maeda, Yorinobu, et al.
Publicado: (2023)

Role of fosaprepitant, a neurokinin Type 1 receptor antagonist, in morphine-induced antinociception in rats
por: Prasoon, Pranav, et al.
Publicado: (2016)

Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation
por: Cabanillas Stanchi, Karin Melanie, et al.
Publicado: (2020)

A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
por: Evans, T. R., et al.
Publicado: (1996)

Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin
por: Yoo, Sun Hong, et al.
Publicado: (2020)

Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
por: Celio, Luigi, et al.
Publicado: (2013)

Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies
por: Cabanillas Stanchi, Karin Melanie, et al.
Publicado: (2019)

Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients
por: Sato, Yumiko, et al.
Publicado: (2014)

Pharmacokinetics of Dexamethasone when Administered with Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting and Differences in Dose-Dependent Antiemetic Effects
por: Shimamoto, Fukutaro, et al.
Publicado: (2021)

Epirubicin-induced Kounis syndrome
por: Liang, Hui-zhu, et al.
Publicado: (2021)

Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis
por: Shen, Li-wen, et al.
Publicado: (2021)

Mitochondrial Role in Oncogenesis and Potential Chemotherapeutic Strategy of Mitochondrial Infusion in Breast Cancer
por: Patel, Prisha S., et al.
Publicado: (2022)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023)

Immortality
por: Carroll, John
Publicado: (2020)

A Case of Hepatocellular Carcinoma with Pulmonary Metastases Treated Successfully with a Combination of Repeated Hepatic Arterial Infusion Epirubicin and Cisplatin Chemotherapy and Systemic Low-Dose Infusion of 5-Fluorouracil
por: Oh, Yun-Jung, et al.
Publicado: (2009)

The Effects of Intravenous Fosaprepitant and Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Neurosurgery Patients: A Prospective, Randomized, Double-Blinded Study
por: Tsutsumi, Yasuo M., et al.
Publicado: (2014)

Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy
por: Ando, Yosuke, et al.
Publicado: (2015)

A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy
por: Kumagai, Hozumi, et al.
Publicado: (2018)

A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis
por: Murakami, Chiaki, et al.
Publicado: (2017)

Antiemetic Prophylaxis with Fosaprepitant and 5-HT(3)-Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
por: Cabanillas Stanchi, Karin Melanie, et al.
Publicado: (2020)

Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis
por: Xu, Xinglu, et al.
Publicado: (2022)

Local and global crosstalk among heterochromatin marks drives DNA methylome patterning in Arabidopsis
por: To, Taiko Kim, et al.
Publicado: (2022)

Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis
por: Lee, Sung Won, et al.
Publicado: (2017)

Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
por: Topham, C., et al.
Publicado: (1991)

Triumph of the immortality-will
por: Ludendorff, Mathilde Spiess, 1877-1966
Publicado: (1982)

Immortal DNA
por: Tuma, Rabiya S.
Publicado: (2005)

The immortality enzyme.
Publicado: (1995)

The new immortality
por: Dunne, J. W
Publicado: (1938)

Cannot write session to /tmp/vufind_sessions/sess_34bqifg9k2kbt5b4son8re80lc